EGFR and cancer: Genetic alterations of c-MET and EGFR were previously identified and implicated in the progression of several cancers (Bastien et al., 2015; Piccirillo et al., 2015; Yamaura et al., 2020) and were also implicated in the resistance of most cancers to any generation of EGFR-TKIs including the latest third-generation series (Paez et al., 2004; Pao et al., 2005; Guo et al., 2020a).